Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- CNRS
- Chalmers University of Technology
- MOHAMMED VI POLYTECHNIC UNIVERSITY
- Universitätskinderklinik Bochum
- CIML2000
- Delft University of Technology (TU Delft)
- FAPESP - São Paulo Research Foundation
- Foundation for Research and Technology-Hellas
- Ghent University
- IFM, Linköping University
- Institute of Physical Chemistry, Polish Academy of Sciences
- Iowa State University
- Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences
- Johns Hopkins University
- Linköping University
- Michigan State University
- Nantes Université
- Nature Careers
- Northeastern University
- Oak Ridge National Laboratory
- Rutgers University
- Ryerson University
- Sorbonne Université
- Stanford University
- THE UNIVERSITY OF HONG KONG
- The Ohio State University
- UiT The Arctic University of Norway
- Umeå universitet
- Universidade do Minho
- Universitat de Barcelona
- Universite de Montpellier
- University of Maryland, Baltimore
- University of North Carolina at Chapel Hill
- University of Oulu
- University of Warsaw, Faculty of Chemistry
- 25 more »
- « less
-
Field
-
University of North Carolina at Chapel Hill | Chapel Hill, North Carolina | United States | 3 days ago
articulated in the School’s Strategic Plan (https://pharmacy.unc.edu/about/oe/strategic-plan/). Our Vision is to be the global leader in pharmacy and pharmaceutical sciences. Our Mission is to prepare leaders
-
Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences | Poland | about 2 months ago
of surfactants’ adsorption properties; determination of physicochemical properties of polyelectrolyte/surfactant complexes; synthesis and characterization of nanoparticles with multicharge surfactants as capping
-
of coated inorganic nanoparticles In vitro assays In vivo analysis WHAT WE ARE LOOKING FOR You hold a thesis-based doctorate in chemistry, biomaterials or related You have proven experience with synthesis and
-
scale and are most often organized at different size scales. They present a great diversity of forms (nanoparticles, porous media, confined fluids, colloids, multimaterials, self-organized media) and
-
nanoparticles) nano-objects for the delivery of personalized therapies for difficult-to-treat diseases. Another aspect of NABI is to develop innovative physics-based therapies such as nanohyperthermia or cold
-
nanoparticles contribute to diseases. Environmental Nanoparticles of interest include those emitted from wildfires, traffic and micro-nanoplastics, the byproduct of degradation of plastics in environmental media
-
manufacturing procedures and the requirement for lymphodepleting chemotherapy, which together limit patient access. Here, we propose an in vivo engineering strategy based on targeted lipid nanoparticles (tLNPs
-
-objects (extracellular vesicles) or synthetic nano-objects (activatable metallic nanoparticles) for the delivery of personalized treatments for hard-to-treat diseases. Studying nano-objects in biological
-
certain aspects of the catalyst samples (e.g. nanoparticle shape, size and alloy composition). Thus, we can unravel the interplay between the nanocatalyst structure and composition and its catalytic
-
nanoparticles (LDE) as a vehicle. Secondary objectives include: stability and cytotoxicity tests, pharmacodynamic, pharmacokinetic, and toxicological studies in mice and cell culture, and proteomic. The research